// App-Quantinova.ai

: the Importance of CD36 Expression in Evaluation of Thrombotic Risk in Patients with Myeloproliferative Neoplasms

Researchers

Presenter

  • Viola Popov

Principal Investigators

  • Meilin Omer

  • Adrian Trifa

  • ION Dumitru

  • Oana Patrinoiu

  • Mihaela Andreescu

  • Horia Bumbea

Medical Centers

  • Rheumatology, Colentina Clinical Hospital, Bucuresti, Romania

  • Rheumatology, Colentina Clinical Hospital, Bucuresti, Romania

  • Genetics, UMF Iuliu Hatieganu, Cluj Napoca, Romania

  • Emergency University Clinical Hospital, Bucharest, Romania

Locations

  • Romania

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Myeloid neoplasms

  • Chronic Myelogenous Leukemia

  • Essential thrombocythemia

  • Polycythemia vera

  • Myelofibrosis

  • Venous thrombosis

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Breakpoint Cluster Region

  • Calreticulin

  • Cluster of Differentiation 31

  • Cluster of differentiation 45

  • Integrin subunit beta 3

  • Janus kinase

  • Tissue factor pathway inhibitor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved